141 related articles for article (PubMed ID: 36463525)
1. Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.
Zhou Y; Yu S; Chen D; Li H; Xu P; Yuan C; Jiang L; Huang M
Mol Pharm; 2023 Feb; 20(2):905-917. PubMed ID: 36463525
[TBL] [Abstract][Full Text] [Related]
2. A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging.
Zhou X; Zheng K; Li R; Chen Z; Yuan C; Hu P; Chen J; Xue J; Huang M
Acta Biomater; 2015 Sep; 23():116-126. PubMed ID: 26004218
[TBL] [Abstract][Full Text] [Related]
3. uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
Huber MC; Mall R; Braselmann H; Feuchtinger A; Molatore S; Lindner K; Walch A; Gross E; Schmitt M; Falkenberg N; Aubele M
BMC Cancer; 2016 Aug; 16():615. PubMed ID: 27502396
[TBL] [Abstract][Full Text] [Related]
4. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
5. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
6. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
7. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
8. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
9. A novel tumor targeting drug carrier for optical imaging and therapy.
Li R; Zheng K; Hu P; Chen Z; Zhou S; Chen J; Yuan C; Chen S; Zheng W; Ma E; Zhang F; Xue J; Chen X; Huang M
Theranostics; 2014; 4(6):642-59. PubMed ID: 24723985
[TBL] [Abstract][Full Text] [Related]
10. Nafamostat mesilate negatively regulates the metastasis of triple-negative breast cancer cells.
Mander S; You DJ; Park S; Kim DH; Yong HJ; Kim DS; Ahn C; Kim YH; Seong JY; Hwang JI
Arch Pharm Res; 2018 Feb; 41(2):229-242. PubMed ID: 29196918
[TBL] [Abstract][Full Text] [Related]
11. Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
Huber MC; Falkenberg N; Hauck SM; Priller M; Braselmann H; Feuchtinger A; Walch A; Schmitt M; Aubele M
Oncotarget; 2016 Jul; 7(28):44062-44075. PubMed ID: 27286449
[TBL] [Abstract][Full Text] [Related]
12. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
Jo M; Takimoto S; Montel V; Gonias SL
Am J Pathol; 2009 Jul; 175(1):190-200. PubMed ID: 19497996
[TBL] [Abstract][Full Text] [Related]
13. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
14. Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat.
Zhou Y; Wu J; Xue G; Li J; Jiang L; Huang M
Biophys J; 2022 Oct; 121(20):3940-3949. PubMed ID: 36039386
[TBL] [Abstract][Full Text] [Related]
15. Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.
Hamurcu Z; Delibaşı N; Geçene S; Şener EF; Dönmez-Altuntaş H; Özkul Y; Canatan H; Ozpolat B
J Cancer Res Clin Oncol; 2018 Mar; 144(3):415-430. PubMed ID: 29288363
[TBL] [Abstract][Full Text] [Related]
16. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.
Csiszar A; Kutay B; Wirth S; Schmidt U; Macho-Maschler S; Schreiber M; Alacakaptan M; Vogel GF; Aumayr K; Huber LA; Beug H
Breast Cancer Res; 2014 Sep; 16(5):433. PubMed ID: 25212966
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
[TBL] [Abstract][Full Text] [Related]
19. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR).
Liu D; Overbey D; Watkinson L; Giblin MF
Bioconjug Chem; 2009 May; 20(5):888-94. PubMed ID: 19354275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
